Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07820995) titled 'Mechanistic Evaluation of Atrasentan in Patients With IgA Nephropathy (IgAN)' on Sept. 9.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: University of Illinois at Chicago
Condition:
IgA Nephropathy (IgAN)
Immunoglobulin A Nephropathy (IgAN)
Intervention:
Drug: atrasentan
Recruitment Status: Not recruiting
Phase: Phase 4
Date of First Enrollment: September 29, 2026
Target Sample Size: 20
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/s...